Goss PE - Search Results

1

Does tumour dormancy offer a therapeutic target?

Goss PE, Chambers AF. Goss PE, et al. Nat Rev Cancer. 2010 Dec;10(12):871-7. doi: 10.1038/nrc2933. Epub 2010 Nov 4. Nat Rev Cancer. 2010. PMID: 21048784 Review.

2

Locoregionally recurrent breast cancer: incidence, risk factors and survival.

Clemons M, Danson S, Hamilton T, Goss P. Clemons M, et al. Cancer Treat Rev. 2001 Apr;27(2):67-82. doi: 10.1053/ctrv.2000.0204. Cancer Treat Rev. 2001. PMID: 11319846 Review.

3

Does treatment at the time of locoregional failure of breast cancer alter prognosis?

Clemons M, Hamilton T, Goss P. Clemons M, et al. Cancer Treat Rev. 2001 Apr;27(2):83-97. doi: 10.1053/ctrv.2001.0205. Cancer Treat Rev. 2001. PMID: 11319847 Review.

4

Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer.

Goss PE. Goss PE. Semin Oncol. 2004 Dec;31(6 Suppl 12):15-22. doi: 10.1053/j.seminoncol.2004.09.022. Semin Oncol. 2004. PMID: 15719597 Review.

5

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Goss PE, et al. J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71. doi: 10.1093/jnci/dji250. J Natl Cancer Inst. 2005. PMID: 16145047 Clinical Trial.

6

The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.

Ryan PD, Goss PE. Ryan PD, et al. Among authors: goss pe. Nat Clin Pract Oncol. 2005 Dec;2(12):596-7. doi: 10.1038/ncponc0360. Nat Clin Pract Oncol. 2005. PMID: 16341095 No abstract available.

7

Aromatase inhibitor withdrawal response in metastatic breast cancer.

Cigler T, Goss PE. Cigler T, et al. Among authors: goss pe. J Clin Oncol. 2006 Apr 20;24(12):1955-6. doi: 10.1200/JCO.2005.03.4108. J Clin Oncol. 2006. PMID: 16622274 No abstract available.

8

Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.

Goss PE. Goss PE. Semin Oncol. 2006 Apr;33(2 Suppl 7):S8-12. doi: 10.1053/j.seminoncol.2006.03.025. Semin Oncol. 2006. PMID: 16730271 Clinical Trial.

9

Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.

Ryan PD, Goss PE. Ryan PD, et al. Among authors: goss pe. Oncologist. 2006 Jul-Aug;11(7):718-31. doi: 10.1634/theoncologist.11-7-718. Oncologist. 2006. PMID: 16880231 Review.

10

Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.

Moy B, Goss PE. Moy B, et al. Among authors: goss pe. Clin Cancer Res. 2006 Aug 15;12(16):4790-3. doi: 10.1158/1078-0432.CCR-06-1535. Clin Cancer Res. 2006. PMID: 16914563 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results